Monitor for any future conversion to a 13D filing, which would signal activist intent. The stake is below 5%, so no immediate market impact expected.
QTTB drugs
QTTB drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $9.34entry
- T+1 · 7d ago −0.11%α +0.26% · $9.33
- T+5 · 20h ago −11.24%α −9.55% · $8.29
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Opaleye Management Inc. and related entities filed an amendment to Schedule 13G disclosing a 3.76% passive stake (1,120,000 shares) in Q32 Bio Inc. as of September 30, 2026. This is a decrease from the prior filing by Point72 Asset Management (which held shares as of August 2026), indicating Opaleye's position is new and below the 5% threshold. The filing is routine and does not signal activist intent.
Key Financial Metrics
Key Facts
- Opaleye Management Inc., Opaleye L.P., and James Silverman filed an amendment to Schedule 13G.
- The group beneficially owns 1,120,000 shares of Q32 Bio common stock.
- The stake represents 3.76% of shares outstanding, based on 29,769,466 shares as of August 3, 2026.
- The filing is passive under Rule 13d-1(c) with no control intent.
- This is a new filing by Opaleye; prior 13G filings for Q32 Bio were by Bank of America (7.4%) and Frazier Life Sciences (5.9%).
Financial Impact
3.76% passive stake valued at approximately $10M based on $267M market cap.
Risk Factors
- No material risks identified from this routine passive stake disclosure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001493152-26-050448 |
| Document: 0001493152-26-050448-index-headers.html | 0001493152-26-050448 |
| Document: 0001493152-26-050448-index.html | 0001493152-26-050448 |
| Document: 0001493152-26-050448.txt | 0001493152-26-050448 |
Track record
23 reports on QTTB
3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +48.47% at T+60 after the Jul 14, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $8.29 Now $8.29 −0.00% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.47 Now $8.29 −2.13% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $8.71 Now $8.29 −4.82% settles Dec 15
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Viewing Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $8.97 Now $8.29 −7.58% settles Dec 3
- Oct 28, 202619d ago SC 13G Neutral 4/10 Entry $9.06 Now $8.29 −8.50% settles Nov 25
- Oct 9, 20265w ago SC 13G Neutral 4/10 Entry $8.74 to $9.36 Now $8.29 −5.15% ▲ +7.09% +10.36% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $8.27 to $8.71 Now $8.29 +0.24% ▲ +5.32% +4.05% vs SPY
- Sep 14, 20269w ago 8-K Neutral 3/10 Entry $10.91 to $8.74 Now $8.29 −24.01% ▼ −19.89% −22.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers